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Background
Increased circulating endothelial microparticles, resulting from vascular endothelium dys-
function, and plasmacytoid dendritic cell activation are both encountered in common
inflammatory disorders. The aim of our study was to determine whether interactions
between endothelial microparticles and plasmacytoid dendritic cells could contribute to
such pathologies.
Design and Methods
Microparticles generated from endothelial cell lines, platelets or activated T cells were
incubated with human plasmacytoid dendritic cells sorted from healthy donor blood or
with monocyte-derived dendritic cells. Dendritic cell maturation was evaluated by flow
cytometry, cytokine secretion as well as naive T-cell activation and polarization. Labeled
microparticles were also used to study cellular interactions.
Results
Endothelial microparticles induced plasmacytoid dendritic cell maturation. In contrast,
conventional dendritic cells were resistant to endothelial microparticle-induced matura-
tion. In addition to upregulation of co-stimulatory molecules, endothelial microparticle-
matured plasmacytoid dendritic cells secreted inflammatory cytokines (interleukins 6 and
8, but no interferon-α) and also induced allogeneic naive CD4+ T cells to proliferate and to
produce type 1 cytokines such as interferon-γ and tumor necrosis factor-α. Endothelial
microparticle endocytosis by plasmacytoid dendritic cells appeared to be required for plas-
macytoid dendritic cell maturation. Importantly, the ability of endothelial microparticles
to induce plasmacytoid dendritic cells to mature was specific as microparticles derived
from activated T cells or platelets (the major source of circulating microparticules in
healthy subjects) did not induce such plasmacytoid dendritic cell maturation. 
Conclusions
Our data show that endothelial microparticles specifically induce plasmacytoid dendritic
cell maturation and production of inflammatory cytokines. This novel activation pathway
may be implicated in various inflammatory disorders and endothelial microparticles could
be an important immunmodulatory therapeutic target.
Key words: endothelial cell-derived microparticles, plasmacytoid, inflammatory diseases,
dendritic cells.
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ABSTRACT
Introduction
Membrane vesiculation is a general physiological
process that leads to the release of cell plasma frag-
ments, called microparticles.1-3 These microparticles are
defined by their size (0.1-1 µm) and can be generated
from nearly every type of cell during activation, injury
or apoptotic processes.1 All microparticles, whatever
their cell origin, have negatively charged phospholipids
– such as phosphatidylserine – in their outer membrane
leaflet, accounting for their procoagulant properties.1-3
They also express proteins, characteristic of their cellu-
lar origin, on their surface and carry proteins packaged
from numerous cellular compartments,4,5 as well as
mRNA.6 Microparticles are different from exosomes,
since these latter are smaller (30-90 nm) and derived
from endocytic compartments leading to an enrichment
of tetraspanin molecules.7 Microparticles can participate
in the maintenance of homeostasis under physiological
conditions. Among the various circulating microparti-
cles, platelet-derived microparticles are the most abun-
dant in the bloodstream, representing between 70 to
90% of circulating microparticles in healthy subjects.8
As shown for apoptotic bodies9 – another form of cell
dust or debris, tumor- or fibroblast-derived microparti-
cles captured by monocytes may induce regulatory
cytokine secretion.10 In addition, microparticles from
activated T cells can deliver differentiation signals to
stem cells.11 In contrast, microparticles can initiate dele-
terious processes if produced in excess1 or when carry-
ing pathogenic constituents or inflammatory signals.12,13
Vascular endothelium aggression may lead to the vesic-
ulation and shedding of endothelial microparticles
(EMP). Increased levels of EMP have been reported in a
variety of pathological situations including thrombo-
sis,3,8 atherosclerosis,14 renal failure,15,16 diabetes,17 graft-
versus-host disease after hematopoietic cell transplanta-
tion18,19 and systemic lupus erythematosus.1,20,21 These
data emphasize the link between endothelial damage,
the release of EMP and the modulation of inflammato-
ry and/or immune responses.
Dendritic cells play a major role in immune respons-
es. They are specialized to capture and present antigens
to T cells.22 Two major subsets of dendritic cells have
been described in humans: conventional dendritic cells
(previously called myeloid dendritic cells) and plasma-
cytoid dendritic cells (PDC).23 These latter represent a
particular population of dendritic cells that were first
identified as the principal cells secreting interferon α
(IFN-α) in response to viral or bacterial stimulation.23 As
such, PDC contribute to the innate anti-viral and anti-
bacterial defense system. Alterations of PDC homeosta-
sis and function with increased production of IFN-α
have been implicated in various autoimmune or inflam-
matory diseases including type I diabetes, psoriasis,
multiple sclerosis, and systemic lupus erythematosus.23-
25 In addition, PDC have been found in the atheroscle-
rotic plaques.26-28 However, a growing body of data
shows that PDC can also be involved in tolerance induc-
tion.29-31 On the other hand in vitro activation of imma-
ture human PDC with ligands for Toll-like receptor
(TLR) 7 or TLR9 (e.g., R848 or type A CpG motifs,
respectively) leads to proinflammatory cytokine pro-
duction and to increased co-stimulatory molecule
expression, subsequently inducing naive T-cell activa-
tion.23 Other factors, such as damage-associated molec-
ular patterns, also induce PDC activation.23,32 Nothing is
known about the capacity of EMP to activate PDC. The
common finding of endothelial damage – associated
with increased EMP release – and PDC activation in sev-
eral inflammatory diseases32 led us to investigate
whether EMP could provide signals that promote phe-
notypic and functional maturation of PDC in vitro.
Design and Methods
Flow cytometry and antibodies
Flow cytometry was performed with a CANTO A
cytometer (BD Biosciences, Le Pont de Claix, France)
using DIVA 6.1 software (BD Biosciences). The following
monoclonal antibodies were used: fluorescein isothio-
cyanate-conjugated BDCA-2 (AC144, Miltenyi Biotech,
Paris, France), CD14 (MYA-4), HLA-DR (B-F1), phyco-
erythrin-conjugated CD40 (mAb89), CD31 (1F11), phy-
coerythrin-Texas red-x (ECD)-conjugated CD41 (P2),
phycoerythrin-cyanin-5 (PC5) CD146 (TEA 1/34), phy-
coerythrin cyanin-7-conjugated CD3 (UCHT1), CD4
(SFCI12T4D11) (Beckman Coulter Immunotech,
Villepinte, France), phycoerythrin-conjugated CD123
(9F5), CCR7 (CD197, clone 2H4), CD83 (HB15e), fluo-
rescein isothiocyanate-conjugated CD80 (MAB104),
CD86 (2331FUN1) and allophycocyanin-conjugated
CD1a (HI149), CD62E (68-5H11) (BD Biosciences).
Fluorescent-conjugated isotype control monoclonal anti-
bodies from the different monoclonal antibody providers
were used. The mean fluorescence intensity ratio was
obtained by dividing the mean fluorescence intensity for
a given marker by the mean fluorescence intensity of the
respective isotype control monoclonal antibody.
Generation and flow cytometry quantification of
microparticles
EMP were prepared from a human microvascular der-
mal endothelial cell line (HMEC-1) as previously
described.33,34 Briefly, confluent HMEC-1 cells were incu-
bated for 24 h with 50 ng/mL TNF-α (Sigma Aldrich,
Saint-Quentin Fallavier, France). Culture supernatants
were collected and cleared from detached cells and cell
fragments by centrifugation at 1200g for 5 min. The
supernatant was then centrifuged twice at 15000g for 90
min (Cambrex, Verviers, Belgium) at 4°C. Pelleted EMP
were resuspended in culture media and used immediate-
ly. The absence of residual TNF-α in EMP samples was
confirmed using ELISA (Diaclone). EMP were also pre-
pared from quiescent HMEC-1 (without TNF-α) as well
as from the human umbilical vein cell line, EAY926
(ATCC CRL-2922) using the same protocol. EMP prepa-
rations were checked for endotoxin contamination using
the Limulus amebocyte lysate assay. Endotoxin content
was always less than 0.05 ng/mL. In some experiments,
the supernatant resulting from the last wash was used as
a control. This supernatant was free of EMP, as demon-
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strated by cytometric analysis. The absence of mycoplas-
ma was confirmed for all cultures using the Mycolasma
PCR detection kit (Venor® GeM, BioValley, Marne la
Vallée, France).
Platelet-derived microparticles were isolated from acid-
citrate-dextrose anticoagulated human blood from
healthy volunteers obtained after written informed con-
sent (Etablissement Français du Sang Bourgogne Franche-
Comté, EFS B/FC, Besançon, France). The platelet-rich
plasma was obtained by centrifugation at 100g for 15
min. This plasma was spun at 1000g for 10 min, the
supernatant was then collected and the platelet-derived
microparticles were pelleted by centrifugation at 20000g
for 2 h at 4°C.12 The purity of platelet-derived microparti-
cle isolation (~95%) was assessed using CD31 and CD41
monoclonal antibody staining. Microparticles derived
from activated T cells were prepared, using the same pro-
tocol as that for EMP, from CD3/CD28 activated periph-
eral blood mononuclear cells isolated from healthy
donors. After isolation on Ficoll-Hypaque (Pharmacia,
Uppsala, Sweden) centrifugation, the peripheral blood
mononuclear cells were activated with CD3/CD28
Dynabeads (Invitrogen, Cergy Pontoise, France) and 600
UI/mL of interleukin (IL)-2 (Proleukine, Sanofi, Paris,
France) for 48 h. Supernatants were collected and T-cell-
microparticles were isolated.
In order to quantify the microparticles, an aliquot of 10
µL of microparticles was labeled using fluorescein isoth-
iocyanate-conjugated annexin V (Annexin V apoptosis
detection kit I, BD Biosciences) according to manufactur-
er’s instructions. In each experiment, control labeling was
performed by incubating annexin V with the supernatant
resulting from the last wash of the microparticle prepara-
tion. A defined number of calibrated 3-µm latex beads
(FlowcountTM beads, Beckman Coulter) was added to the
sample, as an internal standard. Consequently, micropar-
ticles derived from endothelial cells, platelets and activat-
ed T cells were defined as elements with a size comprised
between 0.1-1 µm and positively labeled by fluorescein
isothiocyanate-annexin V.
Generation and isolation of dendritic cells
The GEN 2.2 cell line derived from a PDC leukemia
patient was cultured on MS-5 irradiated feeder cells in
RPMI 1640 Glutamax 1 (InVitrogen, Cergy Pontoise,
France) containing 1 mM sodium pyruvate (Sigma), 20
µg/mL gentamicin (InVitrogen), non-essential amino
acids (InVitrogen) (hereafter referred to as RPMI complete
medium) and 10% heat inactivated fetal calf serum (Life
Technologies, Gaithersburg, MD, USA). Peripheral blood
mononuclear cells from healthy donors were obtained
after written informed consent and isolated by Ficoll-
Hypaque (Pharmacia) centrifugation. Circulating normal
PDC were isolated using immunomagnetic cell sorting
(BDCA-4 cell isolation Kit, Miltenyi Biotec) according to
the manufacturer’s recommendations. After isolation,
PDC purity was controlled by cytometry using
CD123/BDCA-2 monoclonal antibody staining and was
between 94-98%. Monocyte-derived dendritic cells (Mo-
DC) were generated from blood monocytes – isolated by
negative depletion (Negative Monocyte Isolation Kit,
Dynal, InVitrogen) – by a 6-day culture in RPMI 1640,
containing 10% heat inactivated fetal calf serum, 50
ng/mL granulocyte-monocyte colony-stimulating factor
and 20 ng/mL IL-4 (PeproTech, London, UK). At the end
of the culture, the generation of Mo-DC was attested by
a CD1a+ CD14– phenotype. 
Evaluation of dendritic cell maturation
Maturation of freshly isolated PDC was induced by
culture for 18 h in the presence of 10 ng/mL IL-3
(PeproTech) and R848 (1 µg/mL, Invivogen, Toulouse,
France), or CpGA (2 µmol/L, ODN2216, Invivogen), or
recombinant CD40L (1 µg/L, COGER, Paris, France) or by
addition of microparticles (ratio 10 microparticles:1 den-
dritic cell; this corresponds to 5000 microparticles/µL, an
EMP concentration found in vivo in several pathological
situations including myocardial infarction35 and thrombo-
cytopenic purpura36). Mo-DC (6-day culture) were incu-
bated with either lipopolysaccharide from Escherichia coli
(LPS, 2 µg/mL, Sigma) or EMP (10 EMP:1 Mo-DC) for 48
h. To assess the involvement of phosphatidylserine-medi-
ated signaling in Mo-DC maturation, cells were incubat-
ed with EMP or apoptotic cells, as a positive control, (cor-
responding to murine thymocytes submitted to 40 Gray
γ-irradiation- with a ratio of 5 apoptotic cells:1 dendritic
cell), and stimulated 24 h later by lipopolysaccharide. IL-
12(p70) was measured in supernatants (ELISA, BD
OptEIA, BD Biosciences).
Confocal microscopy analyses
PDC were incubated with anti-BDCA-2 monoclonal
antibody (AC144 Miltenyi Biotech) for 30 min at +4°C,
washed and labeled with cyanin 5-conjugated goat anti-
mouse Ig (BD Biosciences). PDC were incubated with
EMP previously labeled with CFSE (5 mM) (Molecular
Probes, Leiden, Netherland) for 2 h at 37°C in a Labtek II
culture chamber (VWR International, Fontenay-sous-
Bois, France). After nuclear staining using DAPI (Mol-
ecular Probes), cells were washed in phosphate-buffered
saline, fixed in 4% paraformaldehyde and mounted
(Fluorescent Mounting Medium, Dako, Trappes, France).
Fluorescent images were acquired on an FV1000 confocal
microscope (Olympus, Rungis, France).
Cytokine production
Culture supernatants were collected from PDC or Mo-
DC incubated with or without TLR ligands or EMP for 18
h. The following cytokines: IL-12p70 (only for Mo-DC),
TNF-α, IL1-β, IL-10, IL-6, IL-8 and transforming growth
factor (TGF)-β were measured in the culture supernatants
using Luminex Technology kits (HCYTO-60 K, Linco,
Millipore, Saint-Quentin en Yvelines, France) on a
Luminex 100® analyzer (Luminex, Austin, TX, USA),
according to the manufacturer’s instructions. Interferon
(IFN)-α was measured by using a Luminex Technology
kit (Biosource, Clinisciences, Montrouge, France).The
minimal detectable concentrations were as follows: 1
pg/mL for IL-12(p70), TNF-α and IL-1β; 2 pg/mL for IL-
10, IL-6 and IL-8; 15 pg/mL for IFN-α; 20 pg/mL for TGF-
β. Intracellular expression of IFN-α by PDC was deter-
mined by flow cytometry using anti-IFN-α monoclonal
antibody (clone LT27:295, Miltenyi Biotec). Brefeldin A
(10 µg/mL, Sigma) was added 3 h before the end of the
activation with TLR ligands or EMP. Staining was per-
formed according to the manufacturer’s recommenda-
tions for fixed and permeabilized cells (Cytofix/cytop-
erm Plus kit, BD Biosciences). 
Capacity of dendritic cells to induce naive CD4+
T-cell proliferation and cytokine production
Mixed leukocyte reactions were performed by cultur-
ing naive CD4+ T cells as responding cells and allogene-
ic dendritic cells stimulated with or without TLR ligands
or EMP as stimulating cells. CD4+ CD45RA+ naive T
cells were isolated from peripheral blood by negative
selection using two sorting kits (CD4 Negative Isolation
Kit, Dynal, InVitrogen and CD45 microbeads, Miltenyi
Biotec) in two steps according to the manufacturers’
instruction. CD4+ CD45RA+ T-cell purity evaluated by
cytometry was between 90 to 94%. Naive CD4+ T cells
were then incubated with allogeneic dendritic cells in
RPMI complete medium containing 10% human serum
(EFS BFC, Besançon, France) for 6 days. T-cell prolifera-
tion was measured using the DELFIA Cell Proliferation
Kit (AD0077P-1, Perkin Elmer, Boston, MA, USA) on a
DELFIA-type reader (DELFIA Envision, 2102 Multilabel
Reader, Perkin Elmer). Five-bromo-2-deoxyuridine (10
µL/mL, Perkin Elmer) was added 18 h before the end of
the mixed lymphocyte reaction. Cytokine secretion by
T cells after mixed lymphocyte reactions was assayed
with a Luminex Kit (HCYTO-60 K, Linco, Millipore).
After 7 days, culture supernatants were collected and
cytokines (IFN-γ, IL-5, IL-4, IL-2, IL-10, IL-17, TNF-α
and TGF-β) of primed T cells were evaluated. CD45RA+
CD4+ naive T cells cultured in complete medium alone
were used as controls. The minimal detectable concen-
trations were the same as described above plus as fol-
lows: 1 pg/mL for IL-5, and IL-17; 2 pg/mL for IFN-γ and
IL-2; 4 pg/mL for IL-4.
Analysis of endothelial microparticle-plasmacytoid
dendritic cell interactions
EMP were added to PDC and incubated at 37°C or 4°C
for 15 to 90 min. After incubation, PDC were washed
three times to remove non-adherent EMP. Then, transfer
of phosphatidylserine or endothelial-specific antigens
(CD146 and CD62E) to PDC was analyzed by cytome-
try. Alternatively, CFSE-labeled EMP were incubated at
different EMP:PDC ratios (1:1, 10:1, 100:1) for 4 h and
PDC were analyzed by cytometry. Sorted CD4+ T cells
were used as a negative control for endocytosis. The role
of sodium-proton exchange and an intact PDC
cytoskeleton for EMP capture was evaluated by pretreat-
ment of PDC for 1 h with either dimethyl amiloride (100
µM) or cytochaline D (20 µM) (Sigma-Aldrich).37
Statistical analysis
Statistical analyses were performed using Sigma Stat
2.0 software (SPSS Inc., Jandel Scientific, Erkrath,
Germany). Group comparisons of parametric or non-
parametric data were performed using the Student’s t test
or Mann Whitney test, respectively. Data were tested for
mean ± S.E.M. A p value less than 0.05 was considered
statistically significant.
Results
Endothelial microparticles increase co-stimulatory
molecule expression on plasmacytoid dendritic cells,
but not on conventional dendritic cells
Interactions between PDC and EMP in vitro have never
been evaluated to date. Since PDC activation and
endothelial damage associated with EMP production are
encountered in similar diseases, we decided to explore
these interactions, as well as the capacity of EMP to
modulate PDC maturation. We first used TNF-α-induced
EMP as representative of inflammatory conditions.
Expression of co-stimulatory (CD80, CD86, CD40) and
activation (HLA-DR, CD83, CCR7) molecules on freshly
isolated PDC or a PDC cell line (GEN2.2) incubated with
EMP was compared to expression of these molecules on
immature PDC or GEN2.2. Incubation of TNF-induced
EMP with freshly isolated PDC for 18 h, induced PDC
maturation, as evidenced by upregulation of the expres-
sion of co-stimulatory molecules, the increase of HLA-
DR molecules, as well as of CD83 and CCR7 as com-
pared to levels in unstimulated immature PDC (Figure
1A-C). The effects of EMP on PDC maturation were
comparable to those induced by classical maturation
agents such as the TLR7 ligand, R848 (Figure 1A-C) and
the TLR9 ligand, CpGA (data not shown). Similar results
were obtained using the GEN2.2 PDC cell line (Figure
1D) or using the endothelial cell line EAY926 as the
source of EMP (data not shown). As shown in Figure 1E,
PDC maturation was still observed for a lower (1:80)
PDC:EMP ratio. In contrast, PDC incubated with the
supernatant resulting from the last wash of EMP, but not
containing EMP, did not induce PDC or GEN2.2 matura-
tion (Figure 1C-D). Moreover, we checked for the
absence of residual TNF-α, bacterial endotoxins or
mycoplasms which could affect dendritic cells matura-
tion. These factors were not detected in any of the cul-
ture conditions (data not shown). We also verified that
EMP derived from TNF-α-stimulated HMEC-1 did not
express the membrane markers HLA-DR, CD83 or
CD123 on their surface and that the increase of such
markers on PDC did not result from EMP uptake by PDC
(data not shown). PDC maturation was also confirmed by
morphological analysis, since EMP-stimulated PDC
acquired dendrites (Figure 1F), a morphological feature of
mature dendritic cells. 
To determine whether EMP-induced maturation was
restricted to PDC or was also observed for conventional
DC, we studied the interactions between EMP and Mo-
DC using the same design experiment as described for
PDC. We did not observe a significant increase of expres-
sion of co-stimulatory molecules on the surface of Mo-
DC exposed to EMP at a ratio of 1 Mo-DC to 10 EMP
(Figure 1G). Only a slight increase of HLA-DR on the sur-
face of Mo-DC was observed in the presence of EMP
(Figure 1G). The same results were observed with a high-
er number of EMP (Mo-DC:EMP ratio 1:80, data not
shown). The TLR4 ligand, lipopolysaccharide, was used
as a control for Mo-DC maturation (Figure 1G).
Altogether, these data showed that EMP generated in the
presence of TNF-α induced PDC maturation, but not
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Mo-DC maturation.
Endothelial microparticle-induced mature 
plasmacytoid dendritic cells are functional 
and secrete inflammatory cytokines
In order to confirm PDC maturation after EMP interac-
tions using a functional assay, we determined cytokines
secreted in the supernatants after culture of PDC with
EMP and by comparison with PDC cultures in the pres-
ence of the TLR7 ligand, R848 or the TLR9 ligand, CpGA.
Immature PDC alone did not produce significant levels of
IL-1β, IL-6, IL-10 or TNF-α (Figure 2A). As expected, PDC
in the presence of R848 or CpGA secreted high levels of
IL-6 and IL-8, and low levels of IL-10 (Figure 2A), while
TGF-β, IL-1α and TNF-β were not detected (data not
shown). In the presence of EMP, PDC also secreted IL-6
and IL-8, although at lower levels than in the presence of
R848 or of CpGA (Figure 2A). The same experiments
were performed using Mo-DC matured in the presence
of lipopolysaccharide or incubated with EMP. In the pres-
ence of EMP, Mo-DC did not secrete significant levels of
IL-6 and exhibited a slight secretion of IL-8 that did not
reach statistical significance (Figure 2B). Lipopoly-
saccharide induced the secretion of IL-12 by Mo-DC
(Figure 2B). In contrast, incubation of Mo-DC with EMP
did not increase IL-12 secretion (Figure 2B). These func-
tional data further confirm that EMP induced PDC matu-
ration, but not Mo-DC maturation.
PDC are the major cells producing IFN-α, as confirmed
in vitro after stimulation with the TLR9 ligand, CpGA
(Figure 2C). However, PDC did not secrete IFN-α when
stimulated by EMP, nor in the presence of R848 (Figure
Figure 1. EMP induce morphological and phe-
notypic maturation of PDC but not of conven-
tional dendritic cells. PDC or the GEN 2.2 PDC
cell line (GEN) were incubated with classical
maturation agents R848 (PDC R848, GEN
R848) or with medium used to generate EMP
but not containing EMP (Med) or with TNF-
induced EMP (PDC EMP, GEN EMP) at the ratio
of 1 dendritic cell to 10 EMP (corresponding to
5000 EMP/µL in vivo)35,36 for 18 h. Co-stimula-
tory and maturation marker expression was
then determined by flow cytometry and com-
pared with the immature unstimulated PDC
(iPDC) or GEN2.2 cell (iGEN) phenotype.
Expression of the PDC-specific marker CD123
did not vary in any of the conditions tested (A).
(A) Histograms from one representative exper-
iment out of eight are shown. (B) Histograms
from one representative experiment out of two
are shown. On each histogram (A,B), values
represent the mean fluorescent intensity (MFI)
ratio (MFIR) obtained by dividing the MFI for a
given marker by the MFI of the respective iso-
type control monoclonal antibody. (C,D)
Histograms represent the mean±S.E.M of HLA-
DR and CD83 expression (expressed as MFIR)
from three independent experiments. *p<0.05.
(E) PDC were incubated for 18 h with TNF-
induced EMP at different PDC:EMP ratios: 1
PDC for 0 (corresponding to medium stimulat-
ed PDC), 1, 5, 10, 20, 40, and 80 EMP and mat-
uration was determined by cytometry. HLA-DR
(P) and CD83 (M) expression (assessed by
MFIR) on PDC incubated with EMP was com-
pared with R848-activated PDC (PDC R848).
Results from two independent experiments are
shown. (F) Morphological analysis of PDC incu-
bated with EMP (PDC EMP) or not (iPDC) con-
firmed PDC maturation as attested by dendrite
acquisition (white arrows) using confocal
microscopy, which also enabled the purity of
the PDC after immunomagnetic cell sorting to
be assessed. PDC are identified here by BDCA-
2 staining (red fluorescence) and nuclear stain-
ing (blue fluorescence). 
Before incubation with PDC, EMP were labeled with CSFE (green fluorescence). Results from one experiment out of two are shown. (G)
Conventional dendritic cells were activated with the TLR4 ligand lipopolysaccharide (Mo-DC LPS) or incubated with EMP (Mo-DC EMP)
at the ratio of 1 Mo-DC to 10 EMP for 48 h. Co-stimulation and maturation marker expression was then determined by flow cytometry
and compared with the immature unstimulated Mo-DC (iMo-DC) phenotype. Expression of CD83, CD86, CD80, CD40 and HLA-DR mol-
ecules increased only in response to lipopolysaccharide stimulation (Mo-DC LPS), but not after EMP incubation (Mo-DC EMP).
Histograms from one representative experiment out of five are shown. Values on each histogram represent MFIR. 
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2C). In addition, significant amounts of IFN-α were not
found in the supernatant of EMP- or R848-stimulated
PDC (data not shown). The same results were observed
whatever the PDC:EMP ratio used (data not shown).
Overall, these data demonstrate that exposure of PDC to
TNF-α-induced EMP increases the secretion of inflam-
matory cytokines by PDC with one major exception,
IFN-α. 
EMP express high levels of phosphatidylserine33 and
phosphatidylserine signaling in conventional dendritic
cells after interactions with apoptotic cells is known to
interfere with dendritic cell maturation.38 We, therefore,
incubated Mo-DC with EMP or apoptotic cells then
stimulated with lipopolysaccharide for 24 h.
Supernatants were collected and IL-12p70 was meas-
ured. Pre-incubation of EMP with Mo-DC reduced
lipopolysaccharide-induced IL-12p70 secretion, such as
observed with apoptotic cell pre-incubation (Figure 2D).
This suggests that Mo-DC respond to an EMP-induced
inhibitory signal. 
Endothelial microparticle-induced mature 
plasmacytoid dendritic cells stimulate naive 
CD4 T-cell proliferation
To further explore the maturation of PDC by EMP,
EMP-stimulated PDC were cultured with naive allogene-
ic CD45RA+ CD4+ T cells. As shown in Figure 3A, naive
CD4+ T cells proliferated significantly in the presence of
EMP-induced mature PDC whereas no proliferation was
observed using unstimulated immature PDC (p=0.025).
The rate of proliferation in the presence of EMP-induced
mature PDC was similar to that observed in the presence
of R848-induced mature PDC (p=0.72) (Figure 3A).
Similar results were obtained using the GEN2.2 cell line
as stimulating cells (Figure 3B). In contrast, Mo-DC stim-
ulated by EMP did not induce significant naive CD4+ T-
cell proliferation in comparison to that induced by
unstimulated Mo-DC (Figure 3B). IL-2 secretion at the
end of the mixed leukocyte reaction was also assessed as
a marker of naive CD4+ T-cell proliferation. While signif-
icant amounts of IL-2 were not detected in CD4+ T cells
co-cultured with immature PDC (mean + S.E.M, 7±4
pg/mL, n=5), increased levels of IL-2 were found in CD4+
T cells cultured with R848-stimulated PDC (1574±436
pg/mL, n=5, p=0.007 vs. immature PDC) or EMP-incu-
bated PDC (590±362 pg/mL, n=5, p=0.008 vs. immature
PDC). 
Endothelial microparticle-induced mature 
plasmacytoid dendritic cells stimulate naive 
Endothelial microparticles and plasmacytoid dendritic cells
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Figure 2. EMP induce cytokine secretion by
PDC, but not by conventional dendritic cells.
(A) Culture supernatants collected from imma-
ture PDC (iPDC), PDC stimulated with the
TLR7 ligand R848 (PDC R848), the TLR9 lig-
and CpGA (PDC CPGA) or with TNF-induced
EMP (PDC EMP, ratio of 1 PDC to 10 EMP) for
18 h were assayed for IL-6, IL-8, and IL-10
using Luminex Technology. EMP-activated PDC
secreted the same cytokine profile as PDC
R848 or PDC CpGA. Data, expressed in
pg/mL, represent the mean±S.E.M of four
independent experiments; *p<0.05;
**p<0.001. Data with PDC CPGA are from one
experiment. (B) Culture supernatants collected
from immature Mo-DC (iMo-DC), Mo-DC stimu-
lated with lipopolysaccharide (Mo-DC LPS) or
with EMP (Mo-DC EMP, ratio 1:10) for 18 h
were assayed for IL-12, IL-6 and IL-8 using
Luminex Technology. Data, expressed in
pg/mL, represent the mean±S.E.M of five
experiments: *p<0.05; **p<0.001. (C)
Percentage of IFN-α+ cells after stimulation of
PDC with R848 (PDC R848), CpGA (PDC
CPGA) or with EMP (PDC EMP, ratio 1:10) for
18 h were assayed for intracellular IFN-α
measured by flow cytometry. Data were com-
pared with unstimulated immature PDC
(iPDC). Dot plot histograms represent expres-
sion of IFN-α on BDCA2+ CD123+ cells.
Histograms from one representative experi-
ment out of three are shown. Similar data
were obtained in cell supernatants (data not
shown). (D) Culture supernatants collected
from immature (iMo-DC), Mo-DC stimulated
with TNF-induced EMP (Mo-DC EMP, ratio of 1
Mo-DC to 10 EMP) or with apoptotic cells
(APO) (Mo-DC APO, ratio: 1 Mo-DC to 5 APO)
for 24 h and then stimulated for 24 h with the
TLR4 ligand lipopolysaccharide (LPS), were
assayed for IL-12(p70) using ELISA. Data,
expressed in pg/mL, represent the
mean±S.E.M. of three independent experi-
ments. 
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CD4 T cells to produce Th1 cytokines
In order to explore CD4+ T-cell polarization after acti-
vation by EMP-induced mature PDC, cytokine secretion
by co-cultured CD4+ T cells was examined and com-
pared with that of CD4+ T cells incubated with imma-
ture PDC and TLR7-stimulated PDC as well as with Th1
or Th2 well-defined conditions (lipopolysaccharide-
stimulated Mo-DC and CD40 plus IL-3 stimulated-PDC,
respectively). Cytokine production was measured
directly in the supernatants after the mixed lymphocyte
reactions. As shown in Figure 3C, naive CD4+ T cells
stimulated by EMP-induced mature PDC secreted Th2-
related cytokines, IL-5 and IL-4, but at non-significant
and variable levels according to the experiments consid-
ered. However, CD4+ T cells primed by EMP-induced
PDC secreted significant levels of Th1-related cytokines,
IFN-γ and TNF-α (Figure 3C). Despite the high levels of
IL-6 produced by PDC after EMP interactions and the
role of IL-6 in Th17 polarization, we did not observe
either IL-17-secreting CD4+ T cells after co-culture with
EMP-induced mature PDC or TGF-β production in any
of the culture conditions (data not shown). The cytokine
profile observed after EMP stimulation was similar to
that of CD4+ T cells stimulated with TLR7-activated
PDC (Figure 3C). Naive CD4+ T cells stimulated by
immature PDC did not secrete these cytokines (Figure
3C). None of these cytokines was detected in the super-
natants from EMP or T cells cultured in medium alone
(data not shown). Comparison with Th1 or Th2 control
conditions (Figure 3C) suggests that EMP-induced
mature PDC favor Th1 polarization, as evidenced by
IFN-γ and TNF-α secretion. 
In contrast to endothelial microparticles,
plasmacytoid dendritic cells do not respond to
platelet- or T-cell-derived microparticles
In order to appreciate the relevance of EMP-induced
PDC maturation, we compared the effects of TNF-α-
induced EMP to the effects of quiescent EMP (i.e., EMP
produced in the absence of TNF-α), of platelet-derived
microparticles (the major form of microparticles found in
the bloodstream of healthy subjects) and of normal T-cell-
derived microparticles. As shown in Figure 4A, quiescent
EMP were as potent as TNF-induced EMP at inducing
PDC maturation, as assessed by co-stimulatory mole-
cule expression (Figure 4A) and naive CD4+ T-cell activa-
tion (data not shown). In contrast, microparticles derived
from platelets or activated T cells did not significantly
induce PDC maturation (Figure 4A). We also studied dif-
ferent ratios of PDC to platelet-derived microparticles,
but whatever the ratio used, the platelet-derived
microparticles did not induce PDC maturation (Figure
4B-C). This suggests that the origin of microparticles –
and particularly the endothelial origin – influences PDC
maturation. 
Concerning the effect of TNF on EMP production, we
observed that TNF-α stimulation of endothelial cells sig-
nificantly increased the number of EMP produced
(Figure 4D). We, therefore, analyzed whether a dose-
effect relationship exists for PDC maturation. As shown
in Figure 4E, we observed a dose-effect of EMP on PDC
maturation. Altogether, this suggests that PDC respond
Figure 3. EMP-induced mature PDC induce allogeneic naive CD4
T-cell proliferation and Th1 cytokine secretion. (A) Proliferation of
naive CD4+ CD45RA+ T cells in response to unstimulated imma-
ture PDC (iPDC), PDC activated by R848 (PDC R848) or to PDC
incubated with TNF-induced EMP at a ratio of 1:10 (PDC EMP) was
analyzed as described in the Design and Methods section. Co-cul-
ture conditions were defined by preliminary experiments and the
adequate ratio is 20,000 PDC to 50,000 naive CD4+ T cells. Basal
CD4+ T-cell proliferation was also measured (Med). Histograms
represent the mean±S.E.M of the four independent experiments.
Results are expressed in europium count (EU count). *p<0.05. (B)
Proliferation of naive CD4+ CD45RA+ T cells in response to unstim-
ulated immature Mo-DC (iMo-DC), Mo-DC activated by lipopolysac-
charide (MO-DC LPS), Mo-DC incubated with EMP at a ratio of 1:10
(Mo-DC EMP), or to GEN2.2 PDC cell line (unstimulated, iGEN; acti-
vated with R848, GEN R848 or incubated with EMP, GEN EMP) was
analyzed as described in the Design and Methods section. Data
are from one representative experiment out of three for GEN2.2
and of two for Mo-DC. Results are expressed in europium counts
(EU count, mean±S.E.M.). *p<0.05; **p<0.001. (C) Culture super-
natants collected from CD4+ T cells co-cultured with immature
(iPDC), with R848-activated PDC (PDC R848), or with PDC incubat-
ed with TNF-induced EMP (PDC EMP) were assessed for Th2-relat-
ed cytokines (IL-4 and IL-5, left panels) and for Th1-related
cytokines (IFN-γ and TNF-α, right panels) using Luminex
Technology. Histograms represent the mean±S.E.M. of five inde-
pendent experiments. Results are expressed in pg/mL for each of
the cytokines analyzed. In order to help data interpretation, addi-
tional controls were performed consisting in Th2 control condi-
tions (using PDC stimulated with CD40L and IL-3, as described)49
and Th1 control conditions (using Mo-DC stimulated with
lipopolysaccharide). *p<0.05; **p<0.001.  
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to a given number of EMP rather than to inflammatory
EMP (i.e., TNF-induced EMP) and, therefore in vivo PDC
may be activated in pathological conditions in which
EMP production is increased, such as injury to the vas-
cular endothelium.
Endothelial microparticle-plasmacytoid dendritic cell
interactions are temperature-dependent and require
sodium-proton exchanges as well as an intact
cytoskeleton
To define the mechanism involved in the maturation
process of PDC induced by EMP, we first determined
whether EMP adhere to PDC and, if so, whether a fusion
between EMP and PDC membranes occurs. In these con-
ditions, a transfer of endothelial antigen to PDC would
occur. Incubation of EMP with PDC did not lead to
endothelial antigen (CD62E or CD146) or phos-
phatidylserine transfer to PDC (data not shown). To fur-
ther evaluate a role of an uptake of EMP by PDC, EMP
were labeled with CFSE before their incubation with
PDC. As shown in Figure 5A-B, significant numbers of
CFSE+ PDC were identified when cells were incubated
with EMP at 37°C whereas incubation at 4°C significant-
ly decreased the percentage of CFSE+ PDC. In contrast,
significant amounts of CFSE were not detected in CD4+
T cells whatever the incubation temperature used (Figure
5A). This suggests that EMP uptake by PDC is tempera-
ture-dependent. To go further, we treated PDC with an
inhibitor of sodium-proton exchange, dimethyl
amiloride or the F-actin depolymerizing agent, cytocha-
Endothelial microparticles and plasmacytoid dendritic cells
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Figure 4. PDC respond to EMP but not to activat-
ed T-cell- or platelet-derived microparticles. (A)
The effects of TNF-α-stimulated EMP (EMP) on
PDC maturation were compared to those of qui-
escent EMP (qEMP), T-cell-derived microparticles
(tMP) or platelet-derived microparticles (PMP).
PDC were activated by R848 (PDC R848) or incu-
bated with TNF-α induced EMP (PDC EMP) or qui-
escent EMP (PDC qEMP) at a ratio of 1 PDC to 10
EMP for 18 h. PDC were also incubated with tMP
and PMP at the same ratio and in the same
experimental conditions. Maturation marker
expression of HLA-DR and CD83 on stimulated
PDC – analyzed by cytometry – was then com-
pared with the expression on immature unstimu-
lated PDC (iPDC). Histograms represent the per-
centage of PDC maturation based on HLA-DR
and CD83 expression with expression on PDC
EMP arbitrarily considered to indicate 100% mat-
uration. Pooled results of four independent exper-
iments are shown. (B) Platelet-derived micropar-
ticle were isolated and analyzed by flow cytome-
try, identified in the FSC vs. SSC gate based on
expression of CD41 and CD31. A representative
experiment out of four is shown. (C) PDC were
incubated for 18 h with PMP at different
PDC:PMP ratios: 1 PDC to 0 (corresponding to
medium-stimulated PDC), 1, 5, 10, 20, and 30
PMP and maturation was determined by cytome-
try. HLA-DR (X) and CD83 (g) expression
(assessed by MFIR) on PDC incubated with PMP
was compared with expression on R848-activat-
ed PDC (PDC R848). Results from one out of two
independent experiments are shown. (D) TNF-α
exposure increases EMP production by the der-
mal endothelial cell line HMEC-1. EMP were pro-
duced as described in the Design and Methods
section. The numbers of EMP produced per cul-
ture flask (50 mL) in basal conditions (q-EMP) or
after TNF-α (50 ng/mL, TNF-EMP) stimulation
were quantified by cytometry. Histograms repre-
sent the mean + S.E.M of the absolute number of
q-EMP or TNF-EMP in a 50 mL culture flask from
six independent productions. *p=0.03. (E) PDC
were incubated for 18 h with TNF-induced EMP
(TNF-EMP, Q) or quiescent EMP (qEMP, L) at dif-
ferent PDC:EMP ratios: 1 PDC to 0 (correspon-
ding to medium-stimulated PDC), 1, 5, 10, 20,
40, and 80 EMP and maturation was determined
by cytometry. CD83 expression (assessed by
MFIR) on PDC incubated with EMP was com-
pared with expression on R848-activated PDC
(PDC R848). Results from two independent
experiments are shown. Of note, 1 EMP:1 PDC
corresponds to 500 EMP/µL; a higher concentra-
tion than that in healthy donors (10 + 10
EMP/µL, personal data). 
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lasin D 1 h prior to the addition of EMP. This treatment
significantly reduced the number of CFSE+ PDC (Figure
5B) and prevented PDC maturation (assessed by co-sti-
mulatory marker expression, data not shown). Taken
together, these data indicate that PDC activation by EMP
is dependent on temperature and requires sodium-proton
exchange and an intact cytoskeleton.
Discussion
Increased circulating EMP related to vascular
endothelial dysfunction and PDC activation are encoun-
tered in similar pathological situations, including vascu-
lar diseases as well as inflammatory diseases.3,8,14-21,23-28
We, therefore, hypothesized that EMP could trigger
PDC maturation and that such an interaction could con-
tribute to the above mentioned inflammatory disorders.
Here, we demonstrate that EMP can indeed induce PDC
maturation, as shown by co-stimulatory molecule
upregulation, inflammatory cytokine secretion, and by
allogeneic naive CD4+ T-cell proliferation. Moreover,
naive CD4+ T cells primed in the presence of EMP-
matured PDC produced mainly type 1 cytokines.
Despite the high levels of IL-6 produce by PDC after
EMP interactions and the role of IL-6 in Th17 polariza-
tion,39 IL-17-secreting CD4+ T cells were not observed
after co-culture with EMP-induced mature PDC. This
could be due to the absence of TGF-β – another critical
cytokine for Th17 differentiation39 – in PDC cultures
after EMP incubation. In contrast to PDC isolated from
healthy volunteers or to the GEN2.2 PDC cell line, EMP
did not induce significant Mo-DC maturation and, in
this setting, reduced lipopolysaccharide-induced IL-12
secretion, as observed after incubation with apoptotic
cells.9,38 Furthermore, microparticles derived from acti-
vated T cells or platelets did not induce PDC matura-
tion. Lastly, PDC maturation induced by EMP required
an active uptake mechanism. Overall, these data sug-
gest a link between vascular endothelial damage and
PDC activation. Maturation of PDC by EMP released
following damage to the endothelium may, therefore,
be implicated in the physiopathology of different
inflammatory and vascular diseases.
The in vivo relevance of our observations remains to be
explored further. The PDC:EMP ratio used here (1:10)
corresponds to 5000 EMP/µL, an EMP concentration
found in vivo in pathological situations.35,36 Infiltration of
mature PDC in injured tissues (such as in atherosclerot-
ic plaques,26-28 in the skin in psoriasis23,32 or systemic
lupus erythematosus)24,25 has been observed in several
chronic inflammatory diseases. Increased expression of
the chemokine receptor CCR740 – as observed here – has
also been reported in trapped dendritic cells found in
atherosclerotic plaques.26 Thus, elevated concentrations
of EMP in response to vascular endothelial damage
and/or endothelial dysfunction15,41 may initiate PDC
migration and subsequent maturation.
Chronic inflammatory diseases are often associated
with uncontrolled IFN-α production by PDC. Such IFN-
α secretion is notably found in systemic lupus erythe-
matosus,42,43 psoriasis23,32 and in atherosclerotic pla-
ques.27,28 In our study, EMP did not cause PDC to secrete
IFN-α. A first hypothesis to explain this is that PDC acti-
vation by EMP may be insufficient to induce IFN-α
secretion. Preliminary data show that EMP are able to
activate nuclear factor-κB (data not shown). Thus, EMP
can be considered, similarly to necrotic cells, as a cell
byproduct that may alert the innate immune system
(i.e., a damage-associated molecular pattern). Necrotic
cells have been reported to activate conventional den-
dritic cell maturation through the TLR2 signaling path-
way44 or CLEC9A.45 Since nucleic acids can be packed
into microparticles,6 one can speculate that EMP-induced
PDC maturation may involve endosomal TLR7 or TLR9.
These receptors are specialized in sensing foreign nucleic
acids. Production of IFN-α is dependent on localization
of TLR9-CpGA interactions in endosomal compart-
ments; interactions in the transferrin+ early endosomes
lead to IFN-α secretion while interactions in the LAMP1+
late endosomes (i.e., lysosomes) are responsible for IL-6
and IL-8 production as well as increased expression of
co-stimulatory molecules.46,47 This may be an explana-
Figure 5. Interaction between EMP and PDC is an active process
dependent on temperature, sodium-proton exchanges and on an
intact actin cytoskeleton. (A) EMP were labeled with CFSE and
incubated with PDC or CD4+ T cells at 37°C or 4°C at the ratio of
1 PDC (or 1 CD4+ T cell) to 100 EMP for 4 h. PDC were identified
based on high expression of CD123. CD4+ T cells were identified
by CD4 expression. After extensive washes, cells were analyzed by
cytometry. Dot plot histograms show the data for one representa-
tive experiment out of three. (B) Histograms represent the mean
of the percentage of PDC (black) or CD4+ T cells (gray) positive for
CFSE after different incubation conditions: 37°C, 4°C, dimethyl
amiloride (DMA), or cytochalasin D (CD) treatment. DMA, an
inhibitor of sodium-proton exchange, or CD, an F-actin depolymer-
izing agent, was incubated with PDC or CD4+ T cells for 1 h before
addition of EMP. Histograms from three or two independent exper-
iments are shown. Results are expressed as mean ± SEM of the
percentage of CFSE+ cells. 
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tion for our observations. In our hands, R848 (a TLR7
ligand) had the same effects as EMP on PDC (namely,
increased expression of co-stimulatory molecules, IL-6
and IL-8 secretion, Th1 CD4+ T-cell polarization and no
secretion of IFN-α). However, pretreatment of EMP by
DNAse I did not prevent PDC maturation (data not
shown), excluding a role of nucleic acids packed into
EMP in PDC maturation. Alternatively, EMP-induced
PDC maturation may use a distinct mechanism that
does not lead to IFN- α secretion. Some C-type lectin
receptors, such as DCIR, on the PDC surface have been
shown to inhibit IFN-α secretion despite co-stimulatory
molecule upregulation.48 EMP contain fragments of the
endothelial cell plasma membrane and may thus
express several potential ligands at their surface that
could induce PDC maturation without IFN-α secretion.
Nevertheless, the release of IL-8 by EMP-stimulated
PDC may lead to neutrophil infiltration and participate
in such inflammation. One may also speculate that
EMP-induced PDC activation occurs early in chronic
inflammatory diseases and that other IFN-α- inducing
agents (such as host defense peptide LL-37/DNA com-
plexes in psoriasis)32 act in parallel to induce IFN-α
secretion. The molecular mechanisms used by EMP to
induce PDC maturation remain to be identified.
However, we observed here that PDC maturation
induced by EMP is an active mechanism resembling
endocytosis. Indeed, like endocytosis,37 EMP/PDC inter-
actions are temperature-dependent and inhibited by
dimethyl amiloride or cytochalasin D treatment.
Microparticles can be released during several physio-
logical or pathological processes from nearly every type
of cell. These microparticles contain membrane, cyto-
plasmic as well as nuclear components, related to their
origin. Circulating microparticles constitute a heteroge-
neous population, differing in cellular origin, antigenic
composition and functional properties.2 Here we
demonstrated that EMP (generated from two different
endothelial cell lines) differed from microparticles
derived from platelets or activated T cells in their
capacity to induce increased expression of co-stimula-
tory molecules on PDC. Data obtained with platelet-
derived microparticles are particularly relevant, since
such microparticles represent the major form of
microparticles in the blood stream in healthy subjects.
Therefore the endothelial origin of microparticles influ-
ences PDC activation.
PDC maturation is not the hallmark of TNF-induced
EMP, since similar maturation was obtained with EMP
derived from unstimulated endothelial cells. This sug-
gests that factors involved in PDC activation are shared
by EMP and quiescent EMP and are not induced by
TNF-α. A recent proteomic study comparing EMP gen-
erated by different agonists identified 432 common pro-
teins in quiescent EMP, plasminogen activator inhibitor
type 1-induced EMP and TNF-induced EMP.5 Variations
in protein abundance in these different EMP were
found.5 Our data are rather in favor of an increase of
EMP in inflammatory conditions (as observed here after
TNF-α stimulation of endothelial cells) being sufficient
to induce PDC maturation. Indeed, increased concentra-
tions of circulating EMP in comparison with levels in
healthy controls have been observed in many inflam-
matory and vascular diseases,35,36 suggesting a dose-
effect relationship for in vitro PDC maturation.
In summary, we show here for the first time that EMP
are able to specifically activate PDC. EMP, resulting
from increased membrane vesiculation of endothelial
cells, could represent a new activating factor for PDC
and thus contribute to inflammation. Control of EMP
production in inflammatory disorders may be beneficial
in order to avoid excessive and inappropriate PDC acti-
vation. EMP may be an important immunmodulatory
therapeutic target.
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